SmartCells, an MIT spinoff, has developed an injectable drug called SmartInsulin that senses high glucose levels and automatically dispenses insulin on demand.
As glucose levels drop off, the drug stabilizes, trapping insulin until the next glucose spike. Such a drug may cut down the number of insulin injections required to once a day and reduce the risk of hypoglycemia (low blood sugar), a potential hazard associated with current diabetic therapies.
Full story here >> Technology Review, Oct. 30, 2008
Walter Derzko
Comments